SEC 13F Intelligence

Duquesne Family Office LLC / ACAD

Duquesne Family Office LLC’s Acadia Pharmaceuticals Inc Position

Does Duquesne Family Office LLC own Acadia Pharmaceuticals Inc (ACAD)? Not currently — the last reported position was 74.4K shares worth $2M in Q2 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$2M
Q2 2023
Shares
74.4K
% of Portfolio
+0.06%
Quarters Held
9
position exited

Position History ACAD

Reported value by quarter
Q2 ’21: $2MQ2 ’21Q3 ’21: $1MQ4 ’21: $2MQ4 ’21Q1 ’22: $2MQ2 ’22: $1MQ2 ’22Q3 ’22: $1MQ4 ’22: $1MQ4 ’22Q1 ’23: $1MQ2 ’23: $2MQ2 ’23filingsflow.com
QuarterSharesValue% of Portfolio
Q2 202374.4K$2M+0.06%
Q1 202374.4K$1M+0.06%
Q4 202274.4K$1M+0.06%
Q3 202274.4K$1M+0.07%
Q2 202274.4K$1M+0.08%
Q1 202274.4K$2M+0.08%
Q4 202174.4K$2M+0.06%
Q3 202174.4K$1M+0.04%
Q2 202174.4K$2M+0.04%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Duquesne Family Office LLC’s full portfolio or all institutional holders of ACAD.